284 related articles for article (PubMed ID: 24426788)
1. Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.
Spender LC; Inman GJ
Cancer Manag Res; 2014 Jan; 6():27-38. PubMed ID: 24426788
[TBL] [Abstract][Full Text] [Related]
2. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
3. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
Cen O; Longnecker R
Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
[TBL] [Abstract][Full Text] [Related]
5. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
Bieging KT; Swanson-Mungerson M; Amick AC; Longnecker R
Cell Cycle; 2010 Mar; 9(5):901-8. PubMed ID: 20160479
[TBL] [Abstract][Full Text] [Related]
7. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?
Allday MJ
Semin Cancer Biol; 2009 Dec; 19(6):366-76. PubMed ID: 19635566
[TBL] [Abstract][Full Text] [Related]
8. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
9. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
11. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Schmitz R; Young RM; Ceribelli M; Jhavar S; Xiao W; Zhang M; Wright G; Shaffer AL; Hodson DJ; Buras E; Liu X; Powell J; Yang Y; Xu W; Zhao H; Kohlhammer H; Rosenwald A; Kluin P; Müller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Ogwang MD; Reynolds SJ; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pittaluga S; Wilson W; Waldmann TA; Rowe M; Mbulaiteye SM; Rickinson AB; Staudt LM
Nature; 2012 Oct; 490(7418):116-20. PubMed ID: 22885699
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
14. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
15. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
16. Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma.
Gutiérrez MI; Bhatia K; Cherney B; Capello D; Gaidano G; Magrath I
Ann Oncol; 1997 Oct; 8(10):987-94. PubMed ID: 9402172
[TBL] [Abstract][Full Text] [Related]
17. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue.
Bornkamm GW
Semin Cancer Biol; 2009 Dec; 19(6):351-65. PubMed ID: 19619654
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway.
Han B; Wang S; Zhao H
Int J Clin Exp Pathol; 2020; 13(1):89-98. PubMed ID: 32055277
[TBL] [Abstract][Full Text] [Related]
20. Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
Mori T; Sairenji T
Virus Genes; 2006 Jun; 32(3):327-34. PubMed ID: 16732486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]